{
    "ticker": "KALV",
    "name": "KalVista Pharmaceuticals, Inc.",
    "description": "KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics for diseases with significant unmet needs. Founded in 2008 and headquartered in Cambridge, Massachusetts, KalVista is primarily known for its work in developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and debilitating swelling episodes. The company\u2019s lead product candidate, KVD900, is an oral, on-demand treatment designed to provide rapid relief from HAE attacks, while KVD824 is being developed as a preventative therapy. KalVista employs a patient-centered approach, leveraging advanced scientific research and clinical development to address the challenges faced by patients suffering from these conditions. The company is committed to bringing meaningful improvements in the lives of patients through its innovative pipeline and has established collaborations with key stakeholders in the healthcare community to further its mission. With a robust research and development strategy, KalVista continues to explore additional applications of its expertise in protease inhibition to develop new treatments for other conditions.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2008",
    "website": "https://www.kalvista.com",
    "ceo": "Andrew Crockett",
    "social_media": {
        "twitter": "https://twitter.com/KalVista",
        "linkedin": "https://www.linkedin.com/company/kalvista-pharmaceuticals"
    },
    "investor_relations": "https://investors.kalvista.com",
    "key_executives": [
        {
            "name": "Andrew Crockett",
            "position": "CEO"
        },
        {
            "name": "Peter E. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "KVD900",
                "KVD824"
            ]
        }
    ],
    "seo": {
        "meta_title": "KalVista Pharmaceuticals, Inc. | Innovative Treatments for Rare Diseases",
        "meta_description": "KalVista Pharmaceuticals, Inc. is dedicated to developing novel therapeutics for hereditary angioedema and other rare diseases. Discover our innovative pipeline and mission.",
        "keywords": [
            "KalVista",
            "Hereditary Angioedema",
            "Biopharmaceuticals",
            "KVD900",
            "KVD824"
        ]
    },
    "faq": [
        {
            "question": "What is KalVista Pharmaceuticals known for?",
            "answer": "KalVista Pharmaceuticals is known for developing innovative treatments for hereditary angioedema."
        },
        {
            "question": "Who is the CEO of KalVista Pharmaceuticals?",
            "answer": "Andrew Crockett is the CEO of KalVista Pharmaceuticals, Inc."
        },
        {
            "question": "Where is KalVista Pharmaceuticals headquartered?",
            "answer": "KalVista Pharmaceuticals is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are KalVista's main products?",
            "answer": "KalVista's main products include KVD900 and KVD824, both aimed at treating hereditary angioedema."
        },
        {
            "question": "When was KalVista Pharmaceuticals founded?",
            "answer": "KalVista Pharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "SAGE",
        "VRTX",
        "AMGN",
        "BMRN"
    ],
    "related_stocks": [
        "BIIB",
        "GILD",
        "CELG",
        "ALNY"
    ]
}